LINDIS Biotech Announces Online Publication of Abstract on Trifunctional Antibody CATUMAXOMAB for the Treatment of HighRisk Non-Muscle-Invasive Bladder Cancer at the ASCO 2022 Annual Meeting

Written by Andreas Villaester on 1st June 2022. Posted in Client News.

• Previous
• Next